Director's Dealing

RNS Number : 6627W

Ergomed plc

19 April 2023

 

Director's Dealing

Guildford, UK - 19 April 2023 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that on 19 April 2023, Dr Miroslav Reljanović, Executive Chairman of Ergomed, transferred 400,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to a former director of the Company.  The transfer took place following an exercise of options under an option agreement dated 5 August 2019 between Dr Reljanović and the former director and the exercise price was 1p per ordinary share.

Following the transfer, Dr Reljanovićholds 9,129,297 ordinary shares representing 17.98% of the Company's issued share capital.

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Miroslav Reljanović
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Transfer of shares
c)	Currency	GBP
d)	Price(s)   and   volume(s)	Price(s)	Volume(s)
		£0.01	400,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	400,000 £0.01 £4,000
f)	Date of the transaction	19 April 2023
g)	Place   of   the   transaction	London Stock Exchange, AIM

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Jonathan Curtain (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy)
Numis Securities Limited (Nominated Adviser and Joint Broker)	Tel: [phone]
Freddie Barnfield / Euan Brown / Jack McLaren
Peel Hunt Securities Limited (Joint Broker) James Steel / Dr Christopher Golden	Tel: [phone]
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Matthew Neal	[e-mail]

About Ergomed plc

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

 

END

 

 

DSHEAPLPFFFDEFA